The Hollings Cancer Center's (HCC) Protocol Review and Monitoring System oversees and ensures the scientific merit, priorities and progress of all cancer clinical studies conducted at the Medical University of South Carolina (MUSC). An HCC Protocol Review Committee (PRC), appointed by the HCC Director and administratively supported by the HCC Clinical Trials Office (CTO), has been given the authority and charge to carry out this mandate. Additionally, the HCC disease-based working groups assist the PRC by virtue of their responsibility for the prioritization of potentially competing clinical trials. The primary goal of the PRC is to ensure that investigator- and industry-initiated cancer research studies nvolving human subjects conducted at MUSC are: 1) scientifically and statistically sound;2) appropriately designed;3) feasible for completion;and 4) in compliance with NIH guidelines for human studies. It also plays an important role in mediating competing studies by requiring an agreed upon institutional prioritization alan, and it closely monitors the accrual progress of studies.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA138313-05
Application #
8456112
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
2013-04-01
Budget End
2014-03-31
Support Year
5
Fiscal Year
2013
Total Cost
$92,268
Indirect Cost
$29,713
Name
Medical University of South Carolina
Department
Type
DUNS #
183710748
City
Charleston
State
SC
Country
United States
Zip Code
29425
Link, Laura A; Howley, Breege V; Hussey, George S et al. (2016) PCBP1/HNRNP E1 Protects Chromosomal Integrity by Translational Regulation of CDC27. Mol Cancer Res 14:634-46
Nelson, Michelle H; Bowers, Jacob S; Bailey, Stefanie R et al. (2016) Toll-like receptor agonist therapy can profoundly augment the antitumor activity of adoptively transferred CD8(+) T cells without host preconditioning. J Immunother Cancer 4:6
Podbielska, Maria; Szulc, Zdzisław M; Kurowska, Ewa et al. (2016) Cytokine-induced release of ceramide-enriched exosomes as a mediator of cell death signaling in an oligodendroglioma cell line. J Lipid Res 57:2028-2039
Sambandam, Yuvaraj; Sakamuri, Sashank; Balasubramanian, Sundaravadivel et al. (2016) RANK Ligand Modulation of Autophagy in Oral Squamous Cell Carcinoma Tumor Cells. J Cell Biochem 117:118-25
Miller, Kayla; Dixit, Suraj; Bredlau, Amy-Lee et al. (2016) Delivery of a drug cache to glioma cells overexpressing platelet-derived growth factor receptor using lipid nanocarriers. Nanomedicine (Lond) 11:581-95
Basher, Fahmin; Jeng, Emily K; Wong, Hing et al. (2016) Cooperative therapeutic anti-tumor effect of IL-15 agonist ALT-803 and co-targeting soluble NKG2D ligand sMIC. Oncotarget 7:814-30
Small, James; Flanagan, Catherine; Armeson, Kent et al. (2016) Family history of cutaneous and noncutaneous malignancies in relation to the risk of keratinocyte carcinoma coupled with another type of cancer: A case-control study. J Am Acad Dermatol 75:1066-1068.e7
Maldonado, Eduardo N; DeHart, David N; Patnaik, Jyoti et al. (2016) ATP/ADP Turnover and Import of Glycolytic ATP into Mitochondria in Cancer Cells Is Independent of the Adenine Nucleotide Translocator. J Biol Chem 291:19642-50
Hendriks, Giel; Derr, Remco S; Misovic, Branislav et al. (2016) The Extended ToxTracker Assay Discriminates Between Induction of DNA Damage, Oxidative Stress, and Protein Misfolding. Toxicol Sci 150:190-203
Paul, Matt R; Levitt, Nicholas P; Moore, David E et al. (2016) Multivariate models from RNA-Seq SNVs yield candidate molecular targets for biomarker discovery: SNV-DA. BMC Genomics 17:263

Showing the most recent 10 out of 311 publications